HR-Positive Metastatic Breast Cancer — A Discussion and Debate on First- and Second-Line Therapy

Featuring perspectives from Dr Sara A Hurvitz and Dr Virginia Kaklamani, including the following topics:

• Introduction: Which Biomarkers and When (0:00)
• Optimizing First-Line Therapy for Patients with Hormone Receptor (HR)-Positive Metastatic Breast Cancer (mBC) (5:31)
• SERENA-6 Trial (19:44)
• Inavolisib (23:08)
• Management of HR-Positive mBC Progressing on a CDK4/6 Inhibitor and Endocrine Therapy (31:46)
• Selective Estrogen Receptor Degraders (41:15)
• AKT (46:13)

CME information and select publications